Showing 4301-4310 of 7009 results for "".
- Invasive GAS Resurgence in Persons Experiencing Homelessnesshttps://reachmd.com/news/invasive-gas-resurgence-in-persons-experiencing-homelessness/2485662/In a population-based surveillance analysis from Toronto and Peel Region, invasive group A Streptococcus infections resurged after the COVID-19 pandemic among adults, with sharply different reported burden between persons experiencing homelessness and housed adults in a two-year dataset dra
- Time-Restricted Feeding Improves Adiposity and Disease Activity in Adults With Crohn’s Diseasehttps://reachmd.com/news/time-restricted-feeding-improves-adiposity-and-disease-activity-in-adults-with-crohns-disease/2485628/For many years, nutritional management in Crohn’s disease has emphasized preventing undernutrition. However, overweight and obesity now affect an estimated 40 percent of patients, introducing metabolic factors that may influence inflammation, treatment response, an
- Addressing Cultural Gaps in Diabetes Prevention and Self-Managementhttps://reachmd.com/news/cultural-gaps-diabetes-prevention-management/2485616/Vietnamese American adults at risk for diabetes may feel motivated to change diet and activity habits yet report low readiness to enroll in formal prevention and management programs. A
- IVL vs Non‑Compliant Balloon: Coronary Compliance and Practical Implications for Calcified PCIhttps://reachmd.com/news/ivl-vs-noncompliant-balloon-coronary-compliance-and-practical-implications-for-calcified-pci/2485599/The BENELUX‑IVL registry used a stepwise IVUS protocol to quantify how coronary artery compliance changes in balloon-crossable, heavily calcified lesions during calcified PCI—clarifying how much the vessel actually yields with escalating lesion preparation. In 28 lesions, CACom was
- Nutrafol Launches Men 50+ Formula Targeting Age-Related Hair Thinninghttps://reachmd.com/news/nutrafol-launches-men-50-formula-targeting-age-related-hair-thinning/2485568/Nutrafol announced an expansion of its men’s portfolio with the launch of Nutrafol Men 50+, a product designed specifically for men aged 50 years and older with thinning hair. According to the company, men entering their 50s ex
- Icotrokinra Maintains Psoriasis Responses With Continuous Treatmenthttps://reachmd.com/news/icotrokinra-maintains-psoriasis-responses-with-continuous-treatment/2485554/Continuous treatment with icotrokinra resulted in durable psoriasis control through one year, while treatment withdrawal was associated with rapid loss of response, according to “Maintenance of Response With Icotrokinra for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results From the Ph
- Risankizumab Maintains Efficacy and Safety in Pediatric Psoriasis Through 52 Weekshttps://reachmd.com/news/risankizumab-maintains-efficacy-and-safety-in-pediatric-psoriasis-through-52-weeks/2485552/Risankizumab maintained or improved clinical response through one year in pediatric patients with moderate-to-severe plaque psoriasis, according to “Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis: Results Through 52 Weeks,” a poster by Nina Magnolo, MD, et al presented a
- Molecular Evolution of SARS-CoV-2 in Immunocompromised Patients: Clinical Insights and Management Strategieshttps://reachmd.com/news/molecular-evolution-of-sars-cov-2-in-immunocompromised-patients-clinical-insights-and-management-strategies/2485522/Replication‑competent SARS‑CoV‑2 persisted for months to years in three immunocompromised patients, driving intra‑host viral evolution and prompting reconsideration of surveillance and treatment strategies. The team performed detailed longitudinal virologic assessmen
- Navigating the Transition: Pediatric to Adult Hospital Care for Complex Conditionshttps://reachmd.com/news/navigating-the-transition-pediatric-to-adult-hospital-care-for-complex-conditions/2485534/Young adults with childhood-onset complex chronic conditions (4Cs) experience substantially worse inpatient outcomes than their peers, with longer hospital stays and higher readmission rates following admission to adult hospitals. In
- Arcutis Reports Positive Phase 2 Data for Infant Atopic Dermatitis Programhttps://reachmd.com/news/arcutis-reports-positive-phase-2-data-for-infant-atopic-dermatitis-program/2485557/Arcutis Biotherapeutics reported positive topline results from the phase 2 INTEGUMENT-INFANT trial evaluating investigational ZORYVE® (roflumilast) cream 0.05% in infants aged 3 months to younger than 24 months with mild to moderate atopic dermatitis (AD).